Nuvectis Pharma to Present in the H.C. Wainwright Global Investment Conference
Nuvectis Pharma, a company specializing in innovative oncology treatments, announced that Ron Bentsur, its CEO, will present an overview at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nuvectis Pharma, a company specializing in innovative oncology treatments, announced that Ron Bentsur, its CEO, will present an overview at the H.C. Wainwright Global Investment Conference.
The event is scheduled for May 24, 2022, at 4:00 PM Eastern Time. A live webcast will be available for approximately 30 days.
Nuvectis's pipeline includes NXP800, a clinical-stage HSF1-pathway inhibitor, and NXP900, a SRC/YES1 kinase inhibitor currently in preclinical testing.
Details
News Market Reaction – NVCT
The recorded move for NVCT in the trading session of this news was -13.46%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FORT LEE, NJ, May 20, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright Global Investment Conference.
A live webcast of the presentation will be available on the link provided below for approximately 30 days.
| Event | H.C. Wainwright Global Investment Conference |
| Date | May 24, 2022 |
| Time | 4:00 PM Eastern Time |
| Link | https://journey.ct.events/view/1ff8e74f-de55-4aad-bddf-9464a6c02784 |
About Nuvectis Pharma
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. The Company's pipeline includes NXP800, a clinical-stage HSF1-pathway inhibitor, and NXP900, a SRC/YES1 kinase inhibitor in IND-enabling pre-clinical testing.
For more information, please visit www.nuvectis.com.
Nuvectis Pharma Contact:
Ron Bentsur
Chairman, Chief Executive Officer and President
Media Relations Contact:
Christopher M. Calabrese
LifeSci Advisors
Tel: 917-680-5608
ccalabrese@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.